Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 07/08

20080182967 - Additives for increasing the separation yield of tall oil soap from black liquors: Methods of increasing the yield of tall oil soap from a black liquor are provided. In an embodiment, the method comprises adding a separation aid to the black liquor. The separation aid comprises alkyl alcohol alkoxylates of formula RO[(CH2CHCH3O)x(CH2CH2O)y]M and combinations thereof, wherein R is straight or branched alkyl of... Agent: Nalco Company

20080182968 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Wilson Sonsini Goodrich & Rosati

20080182969 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Wilson Sonsini Goodrich & Rosati

20080182970 - Using cypin in assays, diagnostics and treatment of cognitive disorders: Disclosed are novel materials and screening methods for diagnosing and monitoring cognitive disorders, as well as for identifying compounds for treating such disorders.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080182971 - Peptide derivatives, and their use for the synthesis of silicon-based composite materials: Methods for forming peptide derivatives using functional moieties and peptide derivatives are provided. Further, methods for using peptide derivatives to form silicon-based composite materials and silicon-based composite materials formed thereby are provided. The silicon-based composite materials may have features on the nanoscale, and the materials may exhibit characteristics derived from... Agent: Dinsmore & Shohl LLP

20080182972 - D-amino acid dehydrogenase and method of making d-amino acids: Polypeptides capable of catalyzing the reductive amination of a 2-ketoacid to its corresponding D-amino acid are provided. The polypeptides can be prepared by mutagenesis of, e.g., a diaminopimelate dehydrogenase. Also provided is a method of making a D-amino acid using a catalytically active polypeptide, wherein a 2-ketoacid is allowed to... Agent: Christie, Parker & Hale, LLP

20080182973 - Peptide conjugated, inosine-substituted antisense oligomer compound and method: A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which... Agent: Perkins Coie LLP

20080182974 - Human cdna clones comprising polynucleotides encoding polypeptides and methods of their use: The invention provides novel human full-length cDNA clones, novel polynucleotides, related polypeptides, related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these cDNA clones, polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080182976 - Antibodies which activate an erythropoietin receptor: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080182975 - Framework-patched immunoglobulins: Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described methods of humanization, which graft CDRs from a donor onto the frameworks of a single acceptor immunoglobulin, we patch segments of framework (FR1, FR2, FR3, and FR4),... Agent: Smith Patent Consulting Consulting, LLC

20080182977 - Molecules associated with cell proliferation: The invention provides human molecules associated with cell proliferation (MACP) and polynucleotides which identify and encode MACP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of MACP.... Agent: Foley And Lardner LLP Suite 500

20080182978 - Anti-ngf antibodies and methods using same: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.... Agent: Pharmacia Corporation Global Patent Department

20080182979 - Fractionation of protein containing mixtures: Thus, a primary aspect of the present invention relates to a method for the fractionation of a protein-containing mixture wherein the protein-containing mixture is selected from the group consisting of milk, milk derived products, milk derived raw materials, vegetable derived products, vegetable derived extracts, fruit derived products, fruit derived extracts,... Agent: Merchant & Gould PC

20080177027 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Wilson Sonsini Goodrich & Rosati

20080177026 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080177028 - Plant pr-5 proteins as mammalian therapeutic agents: The Proteins of the PR-5 family having a lectin-like β barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like β barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional... Agent: Bose Mckinney & Evans, LLP

20080177029 - Process for preparing macrocyclic compounds: e

20080177032 - Catalytically active peptides: A catalytically active peptide comprising an imidazole function in position i flanked by at least one functional group to be amidated in position i+3+4k, where k is an integer equal to or higher than −1 or in position i−4−4n, wherein n is an integer equal to or higher than 0,... Agent: Buchanan, Ingersoll & Rooney Pc

20080177031 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.... Agent: Fulbright & Jaworski, LLP

20080177030 - Protein forming complex with c-fos protein, nucleic acid encoding the same and method of using the same: Proteins that interact with c-Fos, nucleic acids encoding them and inhibitors utilizing them as well as methods for detecting an interaction and screening methods utilizing a protein that interacts with c-Fos are provided. Comprehensive analysis of transcription control factor complexes in a mouse brain cDNA library with c-Fos as a... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080177033 - Self-assembly of peptide-amphiphile nanofibers under physiological conditions: Peptide amphiphile compounds, compositions and methods for self-assembly or nanofibrous network formation under neutral or physiological conditions.... Agent: Benet Group Llc C/o Intellevate

20080177037 - Leucine-based motif and clostridial neurotoxins: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods... Agent: Allergan, Inc.

20080177035 - Methods for making intermediates and oxytocin analogues: More efficient and/or economical methods for synthesizing heptapeptide alcohol analogs of oxytocin are provided along with novel intermediates which are useful in synthesizing such oxytocin analogs. Efficient and economical methods for synthesizing intermediates useful in synthesizing these oxytocin analogs are also provided.... Agent: Fitch Even Tabin And Flannery

20080177036 - Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity: Peptides of formulae I, II and III that selectively activate melanocortin-4 (MC-4) receptor activity.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080177034 - Taspase1 and methods of use: A novel protease, Taspase1, is described. Taspase1 is involved in the cleavage of the myeloid/lymphoid or mixed-lineage leukemia (i.e., MLL) protein, which is required for proper HOX gene regulation. Diagnostic methods utilizing Taspase1 are provided, as well as inhibitors of Taspase1. Methods of using the inhibitors of Taspase1 are also... Agent: Fish & Richardson Pc

20080177038 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Wilson Sonsini Goodrich & Rosati

20080177040 - Alkaline protease: The present invention makes it possible to efficiently produce and provide alkaline proteases having activity even in the presence of a highly concentrated fatty acid, and exhibiting excellent detergency for the removal of a complex stain containing protein, sebum and the like, and therefore being useful as an enzyme to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080177039 - B7-h3 and b7-h4, novel immunoregulatory molecules: The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.... Agent: Fish & Richardson P.c.

20080177041 - Leucine-based motif and clostridial neurotoxins: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods... Agent: Allergan, Inc.

20080177042 - Leucine-based motif and clostridial neurotoxins: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods... Agent: Allergan, Inc.

20080177043 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Sughrue-265550

20080177045 - Monoclonal antibodies against angptl3: Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080177044 - Novel saitohin gene and uses of same: The present invention provides an isolated nucleic acid sequence encoding saitohin (STH), an isolated nucleic acid sequence that hybridizes to said sequence, and a purified protein encoded by said nucleic acid sequences. The present invention also provides a purified STH protein, and a method of making STH protein. The present... Agent: Amster, Rothstein & Ebenstein LLP

20080177046 - Soluble form of carbonic anhydrase ix (s-ca ix), assays to detect s-ca ix, ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes: Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) in body fluids, such as, urine and serum. Said s-CA IX comprises the extracellular domain of CA IX or portions thereof. The Predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase... Agent: Leona L. Lauder

20080177047 - Single-chain antibodies against human insulin-like growth factor i receptor: expression, purification, and effect on tumor growth: A method of inhibiting the growth of hormone dependent tumor cells in a mammal comprises administering to said mammal an insulin-like growth factor receptor (IGF-IR) recombinant antibody, wherein said antibody can be a single-chain recombinant antibody, which can be humanized, capable of blocking agonist interaction with the IGF-IR.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080177048 - Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers: This invention relates to the use of mixed mode chromatography for purification of at least one intact non-aggregated antibody from a mixture containing intact non-aggregated antibodies and undesirable materials, including fragmented or aggregated antibodies, host cell proteins, DNA, endotoxin, and/or virus. This invention further relates to the integration of such... Agent: Townsend And Townsend And Crew, LLP

20080171848 - Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins: The present invention is directed to a method for reducing the onset or incidence of gelation/fibrillation/aggregation during the up- and down-stream processing and purification of peptides, polypeptides and proteins analogs and/or derivatives thereof, including Glucagon-Like Peptides (GLPs). More particularly, the present invention relates to methods of processing and purifying such... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080171850 - Cyclosporine analogue mixtures and their use as immunomodulating agents: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis... Agent: Fish & Richardson P.C.

20080171849 - Peptide cyclisation: A novel method for side chain cyclisation of peptides by means of lactamization is provided.... Agent: Nixon & Vanderhye, PC

20080171851 - Generation of artificial binding proteins on the basis of ubiquitin proteins: The invention relates to modified proteins of the superfamily of “ubiquitin-like proteins”, proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080171852 - Compositions and methods for fusion protein separation: The present invention relates to compositions and methods for fusion protein separation utilizing a peptide linker comprising a novel thrombin cleavage site.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080171853 - Somatostatin antagonists: The present invention is directed to a method for synthesizing a peptide using solid-state chemistry in which at least one amide bond is N-methylated, wherein said method of synthesis utilizes N-Boc protected amino acids. For example, the a peptide is first synthesized using N-BOC protected amino acids and 4-methylbenzylhydrylamine functionalized... Agent: Alan F. Feeney, Esq. Biomeasure, Incorporated

20080171854 - Tumor suppressor gene, p47ing3: The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.... Agent: Townsend And Townsend And Crew, LLP

20080171855 - Polyvalent protein complex: The invention provides for a polyvalent protein complex (PPC) comprising two polypeptide chains generally arranged laterally to one another. Each polypeptide chain typically comprises 3 or 4 “v-regions”, which comprise amino acid sequences capable of forming an antigen binding site when matched with a corresponding v-region on the opposite polypeptide... Agent: Immunomedics, Inc.

20080171856 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a... Agent: Sughrue Mion, PLLC

20080171857 - Process for the purification of recombinant granulocyte-colony stimulating factor: The present invention describes a novel process for large scale purification of therapeutic grade quality of recombinant human G-CSF from microbial cells, wherein the protein is expressed as inclusion bodies. The process involves the novel use of Hydrophobic Interaction Chromatography (HIC) step to purify G-CSF eluted from a cation exchange... Agent: Venable LLP

20080167443 - Novel chelating agents and highly luminescent and stable chelates and their use: This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or... Agent: Buchanan, Ingersoll & Rooney PC

20080167444 - Abc transporter inhibitor: It is an object of the present invention to provide an ABC transporter inhibitor whereby the multi-drug resistance against anticancer drugs caused by amplification and expression of MDR1 gene, which is the most serious problem in chemotherapy for cancer, or the resistance against antifungal agents in mycotic diseases can be... Agent: Drinker Biddle & Reath (dc)

20080167445 - Enhanced oil recovery compositions comprising proteins and surfactants and methods of using the same: Disclosed herein are compositions comprising a surfactant and a protein system, where the protein system comprises proteins and stress proteins obtained by the process of fermenting yeast to obtain a fermentation mixture; subjecting the fermentation mixture to stress conditions to obtain a post-fermentation mixture; and centrifuging the post-fermentation mixture and... Agent: Biotechnology Law Group C/o Portfolioip

20080167446 - Rgd-enriched gelatine-like proteins with enhanced cell binding: The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at... Agent: Ip Patent Docketing Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080167447 - Extraction of gelatin: A process for extracting gelatin from a marine invertebrate, comprising the steps of: 1) pre-treating a collagen-containing portion of the marine invertebrate with an alkali; and 2) extracting gelatin from the pre-treated collagen-containing portion with a weak acid solution at a temperature sufficient for conversion of collagen to gelatin to... Agent: Pearl Cohen Zedek Latzer, LLP

20080167448 - Antibodies to tumor associated proteins: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys C/o Morrison & Foerster LLP

20080167449 - Methods of generating variant proteins with increased host string content and compositions thereof: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.... Agent: Morgan, Lewis & Bockius, LLP

20080167450 - Methods of purifying proteins: The present invention relates to methods of purifying and analyzing preparations of Fc domain containing polypeptides comprising binding said polypeptide to protein A, more particularly to a protein A column, and eluting with a pH gradient elution system. This method enhances separation of aggregates, multimers and modified versions of the... Agent: Amgen Inc.

20080167451 - Method for isolating an intestinal cholesterol binding protein: The invention describes a method for isolating an intestinal protein which is able to bind cholesterol and/or cholesterol uptake inhibitors.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080167452 - Process for purification of human growth hormone: Adding enough organic solvent to hydrophobic interactive chromatography elution buffer eliminates the need to also add detergent to the buffer when separating poly-peptides. For example, adding about 50% acetonitrile to detergent-free elution buffer enaibls one to separate full-length human growth hormone from its various truncated forms, to obtain hGH with... Agent: Pharmaceutical Patent Attorneys, LLC

20080161535 - Thickening and wetting agents: A rosin alcohol alkoxylated with 0-200 moles of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide, butylene oxide, and combinations thereof per mole of alcohol is provided. A thickening agent and a method for making the thickening agent includes an alkoxylated rosin alcohol... Agent: Cognis Corporation Patent Department

20080161536 - Vancomycin b hydrochloride crystalline form 1: Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20080161537 - Selective radiolabeling of biomolecules: Provided herein are methods for introducing fluorine atom onto a biomolecule comprising: (i) providing a linker comprising a thiol-reactive terminus and an azido/alkyne-reactive terminus; (ii) reacting the thiol-reactive terminus of the linker with a biomolecule comprising at least one thiol group or a reactive derivative thereof; and (iii) subsequently reacting... Agent: General Electric Company Global Research

20080161538 - Pan-antiviral peptides: Methods for preparing viral neuraminidase inhibitors including antiviral peptides by specifically chemically modifying disulfide bonds in precursor molecules. A method of inhibiting viral neuraminidases by administering a viral neuraminidase inhibitor comprising an antiviral peptide prepared by the above methods and inhibiting the viral neuraminidase. Therapeutics for inhibiting viral neuraminidases, including... Agent: Kohn & Associates, Pllc

20080161539 - Modified human four helical bundle polypeptides and their uses: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080161540 - Il-17a/f heterologous polypeptides and therapeutic uses thereof: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present... Agent: Heller Ehrman LLP

20080161541 - Fc variants with increased affinity for fcyriic: The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20080161542 - Bridgehead labelled compounds and methods of using the same: The present invention relates to compounds having the general formula: Y-L-BFR-X wherein BFR is a bridged fused ring system; Y is a targeting group; L is optionally present and is a linker for coupling Y to BFR; and X is halogen (e.g., radiohalogen) or a functional group for labelling.... Agent: Mallinckrodt Inc.

20080161543 - Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.... Agent: Allergan, Inc.

20080161544 - Chromatographic separation of therapeutic polypeptides: The present invention is directed to the purification and commercialization of therapeutic polypeptides that have. In one aspect of the invention, a method of purifying Interferon β-1b using size exclusion chromatography is provided. In another aspect of the invention, a method of purifying a polypeptide using size chromatography is provided.... Agent: Novartis Corporate Intellectual Property